AR034517A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
AR034517A1
AR034517A1 ARP020102278A ARP020102278A AR034517A1 AR 034517 A1 AR034517 A1 AR 034517A1 AR P020102278 A ARP020102278 A AR P020102278A AR P020102278 A ARP020102278 A AR P020102278A AR 034517 A1 AR034517 A1 AR 034517A1
Authority
AR
Argentina
Prior art keywords
formulation
pharmaceutical formulation
pharmaceutically active
basic ingredient
active basic
Prior art date
Application number
ARP020102278A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR034517A1 publication Critical patent/AR034517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

Una formulación farmacéutica oral que comprende Iota-Carragenina, uno o más polímeros gelificantes neutros y un ingrediente básico farmacéuticamente activo; cuya formulación inhibe la liberación del ingrediente básico farmacéuticamente activo de la formulación a un pH ácido; un proceso para la fabricación de dicha formulación; y el uso de dicha formulación en la medicina.
ARP020102278A 2001-06-21 2002-06-18 Formulacion farmaceutica AR034517A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR034517A1 true AR034517A1 (es) 2004-02-25

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102278A AR034517A1 (es) 2001-06-21 2002-06-18 Formulacion farmaceutica

Country Status (31)

Country Link
US (1) US7700582B2 (es)
EP (1) EP1401502B1 (es)
JP (1) JP2005501024A (es)
KR (1) KR20040011542A (es)
CN (1) CN1518462A (es)
AR (1) AR034517A1 (es)
AT (1) ATE314093T1 (es)
AU (1) AU2002345463B2 (es)
BG (1) BG108516A (es)
BR (1) BR0210489A (es)
CA (1) CA2450449A1 (es)
CO (1) CO5550466A2 (es)
CZ (1) CZ299859B6 (es)
DE (1) DE60208369T2 (es)
DK (1) DK1401502T3 (es)
EE (1) EE200400028A (es)
ES (1) ES2254699T3 (es)
HU (1) HUP0400850A3 (es)
IL (2) IL159217A0 (es)
IS (1) IS2347B (es)
MX (1) MXPA03011546A (es)
MY (1) MY130332A (es)
NO (1) NO20035627D0 (es)
NZ (1) NZ530086A (es)
PL (1) PL366432A1 (es)
RU (1) RU2323006C2 (es)
SI (1) SI1401502T1 (es)
SK (1) SK286238B6 (es)
UA (1) UA77959C2 (es)
WO (1) WO2003000293A1 (es)
ZA (1) ZA200309316B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
AU2002348279C1 (en) * 2001-11-13 2008-09-04 Astellas Pharma Inc. Soluble drug extended release system
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006046954A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
CA2677201C (en) * 2007-02-01 2015-11-17 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
EP2262486B1 (en) 2008-08-01 2013-01-02 KRKA, Tovarna Zdravil, D.D., Novo Mesto Quetiapine composition
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) * 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (es) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5760235A (en) 1992-03-04 1998-06-02 Gyogyszerkutato Intezet Kft. Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof
TW223629B (es) 1992-03-06 1994-05-11 Hoffmann La Roche
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5783563A (en) 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
SI9620037A (sl) 1995-02-17 1998-02-28 Basf Aktiengesellschaft Novi trombinski inhibitorji
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
AU3496297A (en) 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
EP1107791B8 (en) * 1998-09-04 2007-11-07 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
IL143987A (en) 1999-01-13 2005-12-18 Astrazeneca Ab Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
EE200400028A (et) 2004-04-15
NO20035627D0 (no) 2003-12-15
CZ20033491A3 (en) 2004-03-17
BG108516A (en) 2004-12-30
CO5550466A2 (es) 2005-08-31
ATE314093T1 (de) 2006-01-15
IL159217A (en) 2009-02-11
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
IL159217A0 (en) 2004-06-01
ES2254699T3 (es) 2006-06-16
EP1401502A1 (en) 2004-03-31
IS7081A (is) 2003-12-16
UA77959C2 (en) 2007-02-15
AU2002345463B2 (en) 2007-08-30
CA2450449A1 (en) 2003-01-03
CN1518462A (zh) 2004-08-04
RU2003136155A (ru) 2005-05-20
MXPA03011546A (es) 2004-03-19
DK1401502T3 (da) 2006-04-10
HUP0400850A3 (en) 2010-10-28
SI1401502T1 (sl) 2006-06-30
EP1401502B1 (en) 2005-12-28
IS2347B (is) 2008-03-15
SK15912003A3 (sk) 2004-05-04
ZA200309316B (en) 2005-02-28
DE60208369T2 (de) 2006-08-24
SK286238B6 (sk) 2008-06-06
MY130332A (en) 2007-06-29
US20040242536A1 (en) 2004-12-02
JP2005501024A (ja) 2005-01-13
NZ530086A (en) 2005-09-30
DE60208369D1 (de) 2006-02-02
RU2323006C2 (ru) 2008-04-27
BR0210489A (pt) 2004-06-22
HUP0400850A2 (hu) 2004-08-30
CZ299859B6 (cs) 2008-12-17
WO2003000293A1 (en) 2003-01-03
US7700582B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
AR034517A1 (es) Formulacion farmaceutica
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
ECSP083351A (es) Composiciones farmacéuticas
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
UY25544A1 (es) Forma de dosificación de nefazodona
ATE541562T1 (de) Ibuprofen-suspension
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
NO20062668L (no) Orale formuleringer av desoxypeganin og anvendelser derav
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
WO2005051350A3 (en) Water dispersible tablet
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
SE0001916D0 (sv) Novel formulation
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
UY27345A1 (es) Formulación farmacéutica.
AR046955A1 (es) Preparacion efervescente de una sustancia basica farmaceuticamente activa
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
ECSP992975A (es) Forma de dosificacion de nefazodona

Legal Events

Date Code Title Description
FB Suspension of granting procedure